BioCentury | Jan 22, 2021
Product Development

Lilly, AbCellera mAb could enable broad deployment for COVID without taxing infusion centers

...hospital resources and the risk of exposing uninfected individuals at infusion centers. Bamlanivimab and casirivimab/imdevimab from Regeneron Pharmaceuticals Inc....
...vs. four in the placebo group. No staff members in the pre- or post-exposure groups died.Regeneron...
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...LSE:TILS; NASDAQ:TLSA) hired Neil Graham as CMO. Graham was VP of strategic program direction, immunology and inflammation at Regeneron Pharmaceuticals Inc....
BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

...the incoming Biden administration’s stance on vaccine distribution, which it made public last week.Doses under Regeneron...
...agreement, Regeneron is supplying doses to treat about 300,000 people. Roche (SIX:ROG; OTCQX:RHHBY) is collaborating with Regeneron...
...HER1) - Epidermal growth factor receptorHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 BC Staff Regeneron...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

...blocking implementation of the MFN rule that courts issued in cases filed by BIO and Regeneron Pharmaceuticals Inc....
...notice and comment procedures required by the Administrative Procedure Act.”In its Dec. 30 ruling granting Regeneron’s...
...allow private plans participating in the individual marketplace to access a similar rate.” Steve Usdin Biotechnology Innovation Organization Regeneron Pharmaceuticals Inc. Drug...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...—Inmazeb atoltivimab, maftivimab and odesivimab-ebgn from Regeneron Pharmaceuticals Inc....
BioCentury | Dec 30, 2020
Product Development

Regeneron finds enough signal to continue testing COVID-19 antibody cocktail in subset of hospitalized patients

...By Karen Tkach Tuzman, Senior Editor Data announced by Regeneron Tuesday carves out a potential window...
...patients, an indication where mAbs from the company and its competitors have yet to prove out.Regeneron Pharmaceuticals Inc....
...virological benefits were limited in seropositive patients who had developed their own antibodies to the virus.Regeneron...
BioCentury | Dec 22, 2020
Product Development

Bump in the road for AZ and Amgen’s severe asthma candidate

...Nucala mepolizumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and Dupixent dupilumab from Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc....
BioCentury | Dec 21, 2020
Translation in Brief

Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more

...Revlimid lenalidomide from Bristol Myers Squibb Co. (NYSE:BMY). Blocking an another interleukin pathway reduces inflammationIn Science Immunology, Regeneron Pharmaceuticals Inc....
...2 SARS-CoV-2 S – SARS-CoV-2 spike protein Danielle Golovin Revlimid, lenalidomide (cdc 501, CC-5013) Theravectys S.A. Novartis Institutes for BioMedical Research Regeneron Pharmaceuticals Inc. Eureka...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...from Warp Speed, presumably because of its ties to China.In contrast, COVID-19 mAb development by Regeneron Pharmaceuticals Inc....
...been propelled by cash infusions from Operation Warp Speed. The initiative provided $450 million to Regeneron...
...devoted myself to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...succeed despite the failure of mAbs from Regeneron Pharmaceuticals...
...it was unlikely to help hospitalized patients. Regeneron...
...in hospitalized patients” than the Lilly-AbCellera and Regeneron...
Items per page:
1 - 10 of 1818
BioCentury | Jan 22, 2021
Product Development

Lilly, AbCellera mAb could enable broad deployment for COVID without taxing infusion centers

...hospital resources and the risk of exposing uninfected individuals at infusion centers. Bamlanivimab and casirivimab/imdevimab from Regeneron Pharmaceuticals Inc....
...vs. four in the placebo group. No staff members in the pre- or post-exposure groups died.Regeneron...
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...LSE:TILS; NASDAQ:TLSA) hired Neil Graham as CMO. Graham was VP of strategic program direction, immunology and inflammation at Regeneron Pharmaceuticals Inc....
BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

...the incoming Biden administration’s stance on vaccine distribution, which it made public last week.Doses under Regeneron...
...agreement, Regeneron is supplying doses to treat about 300,000 people. Roche (SIX:ROG; OTCQX:RHHBY) is collaborating with Regeneron...
...HER1) - Epidermal growth factor receptorHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 BC Staff Regeneron...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

...blocking implementation of the MFN rule that courts issued in cases filed by BIO and Regeneron Pharmaceuticals Inc....
...notice and comment procedures required by the Administrative Procedure Act.”In its Dec. 30 ruling granting Regeneron’s...
...allow private plans participating in the individual marketplace to access a similar rate.” Steve Usdin Biotechnology Innovation Organization Regeneron Pharmaceuticals Inc. Drug...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...—Inmazeb atoltivimab, maftivimab and odesivimab-ebgn from Regeneron Pharmaceuticals Inc....
BioCentury | Dec 30, 2020
Product Development

Regeneron finds enough signal to continue testing COVID-19 antibody cocktail in subset of hospitalized patients

...By Karen Tkach Tuzman, Senior Editor Data announced by Regeneron Tuesday carves out a potential window...
...patients, an indication where mAbs from the company and its competitors have yet to prove out.Regeneron Pharmaceuticals Inc....
...virological benefits were limited in seropositive patients who had developed their own antibodies to the virus.Regeneron...
BioCentury | Dec 22, 2020
Product Development

Bump in the road for AZ and Amgen’s severe asthma candidate

...Nucala mepolizumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and Dupixent dupilumab from Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc....
BioCentury | Dec 21, 2020
Translation in Brief

Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more

...Revlimid lenalidomide from Bristol Myers Squibb Co. (NYSE:BMY). Blocking an another interleukin pathway reduces inflammationIn Science Immunology, Regeneron Pharmaceuticals Inc....
...2 SARS-CoV-2 S – SARS-CoV-2 spike protein Danielle Golovin Revlimid, lenalidomide (cdc 501, CC-5013) Theravectys S.A. Novartis Institutes for BioMedical Research Regeneron Pharmaceuticals Inc. Eureka...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...from Warp Speed, presumably because of its ties to China.In contrast, COVID-19 mAb development by Regeneron Pharmaceuticals Inc....
...been propelled by cash infusions from Operation Warp Speed. The initiative provided $450 million to Regeneron...
...devoted myself to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...succeed despite the failure of mAbs from Regeneron Pharmaceuticals...
...it was unlikely to help hospitalized patients. Regeneron...
...in hospitalized patients” than the Lilly-AbCellera and Regeneron...
Items per page:
1 - 10 of 1818